|3 Months Ended|
Mar. 31, 2022
Note 14 — Subsequent Events
On April 8, 2022 the Company entered into a sales agreement with Cowen (the “2022 Sales Agreement”) under which we may from time to time issue and sell ADSs representing our ordinary shares through Cowen in ATM offerings for an aggregate offering price of up to $200 million. In April 2022, the Company sold 5,000,000 ADSs representing 30,000,000 ordinary shares resulting in gross proceeds to the Company of $8,750,000 prior to deducting commissions payable under the 2022 Sales Agreement and issuance costs. As of May 9, 2022, $191,250,000 remained available for sale under the 2022 Sales Agreement.
On May 4, 2022 the Company announced that it had appointed Dr. Joanna Brewer as its Chief Scientific Officer with immediate effect.
The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef